Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

Stopped early · Phase 2

Conditions studied: Childhood Brain Tumor

In brief

RATIONALE: Current therapies for children with primary malignant brain tumors provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with primary malignant brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children with primary malignant brain tumors.

Key facts

Study ID

NCT00003476

Run by

Burzynski Research Institute

People needed

8

Starts

1996-03-01

Expected to finish

2012-01-01

Last updated by the study team

2017-08-24

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Burzynski Clinic — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.